News
The FDA has accepted for Priority Review the sBLA for aflibercept injection 8mg for the treatment of macular edema following RVO and for monthly dosing in approved indications.
Zacks Investment Research on MSN5h
Biotech Stock Roundup: BMY Down on Study Data, Updates From REGN & MoreThis was a low-key week for the biotech sector before the onset of the first-quarter earnings season. Biotech giant Bristol ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback